IDEAYA Biosciences Initiates Clinical Trial for New Drug to Address Solid Tumors and Cancer Drug Resistance
IDEAYA Biosciences, Inc., a precision medicine oncology company in the United States, announced that...
World's First! China's Radiomedicine's Nuclear Drug 99mTc-3PRGD2 Broad-Spectrum Tumor Imaging Agent Approved for Market Launch
On April 2, 2026, the China National Medical Products Administration approved the market launch of T...
U.S. Azurity Pharmaceuticals Launches New Oral Solution for Treating Attention Deficit Hyperactivity Disorder
Azurity Pharmaceuticals, Inc., a company dedicated to providing innovative pharmaceutical solutions ...
GEA and Hovione Collaborate to Launch Solution Accelerating Smart Tablet Manufacturing Development
German company GEA and Portuguese firm Hovione have joined forces to launch the SimpleCT solution, a...
$400 Million to Buy a "Pharmaceutical Brain": Anthropic Makes Its First Acquisition of AI Biotech Company Coefficient Bio
Claude's parent company has started buying "pharmaceutical brains." Anthropic has acquired AI biotec...
Consumer Investigation Launched for Dietary Supplement Berberine Patch
Wayne, New Jersey, April 1, 2026 - As social media buzz increases around berberine-based weight mana...
U.S. Medical Research Suggests Children with Low-Risk Hodgkin Lymphoma May Avoid Radiotherapy
A U.S. Phase II clinical trial shows that after 8 weeks of treatment with a dose-intensive modified ...
Alphamab Oncology Announces HER2 Bispecific Antibody Combination Therapy Meets Primary Endpoint in Phase III Clinical Study in Suzhou, China
On April 1, 2026, Alphamab Oncology announced that its self-developed HER2 bispecific antibody Enbet...
European Medicines Agency Releases Draft on Virtual Control Groups to Reduce Animal Testing in Drug Development
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) rec...
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Clinical Trial Results of HRS-1893 in Obstructive Hypertrophic Cardiomyopathy
Hengrui Pharma and Braveheart Bio recently announced positive progress in the Phase 2 clinical trial...